Study drug for immune thrombocytopenia with low platelets
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary ITP (your platelet problem is from an immune cause, not another condition).
- Your platelet count is low and stays low: under 50 (in the trial’s units).
- You have no severe bleeding in the past month or at the time of screening.
- Your ITP has lasted: either 3–12 months (persistent) or more than 12 months (chronic).
- You have not had a significant bleeding episode within the last 4 weeks.
- You have not had a spleen removal surgery (splenectomy) in the last 3 months, and you don’t plan one during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called SG301-SC for people with primary immune thrombocytopenia (ITP) whose platelet counts stay low even after standard treatments. The goal is to see if it is safe and helps raise platelets, reducing bleeding risk.
This trial tests an experimental oral medication called TQB3473 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets causing low counts and bleeding risk. The goal is to see if the drug can safely improve platelet counts and reduce bleeding symptoms.
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
This trial tests a new medicine for children with a condition called immune thrombocytopenia (ITP), which causes low blood platelets and easy bruising or bleeding. It may help increase platelet counts when standard treatments haven't worked.
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.